HC Wainwright Analysts Boost Earnings Estimates for AKBA

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities researchers at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Akebia Therapeutics in a research report issued on Thursday, October 30th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter, up from their prior estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.04 EPS, FY2026 earnings at $0.31 EPS and FY2027 earnings at $0.26 EPS.

AKBA has been the subject of several other reports. BTIG Research dropped their price objective on Akebia Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akebia Therapeutics in a research note on Wednesday, October 8th. Zacks Research cut Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised shares of Akebia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Akebia Therapeutics Price Performance

Shares of AKBA stock opened at $2.09 on Monday. The company has a quick ratio of 1.84, a current ratio of 1.98 and a debt-to-equity ratio of 1.61. Akebia Therapeutics has a twelve month low of $1.52 and a twelve month high of $4.08. The company has a market cap of $554.15 million, a P/E ratio of -12.29 and a beta of 0.68. The business has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $3.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its holdings in Akebia Therapeutics by 207.2% during the first quarter. New York State Common Retirement Fund now owns 38,400 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 25,900 shares during the last quarter. AIGH Capital Management LLC purchased a new stake in shares of Akebia Therapeutics during the first quarter valued at approximately $5,616,000. Mackenzie Financial Corp increased its position in shares of Akebia Therapeutics by 75.5% during the first quarter. Mackenzie Financial Corp now owns 237,558 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 102,166 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Akebia Therapeutics during the first quarter valued at approximately $88,000. Finally, Vanguard Group Inc. increased its position in shares of Akebia Therapeutics by 16.6% during the first quarter. Vanguard Group Inc. now owns 12,685,803 shares of the biopharmaceutical company’s stock valued at $24,357,000 after acquiring an additional 1,801,603 shares during the last quarter. Institutional investors own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.